BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 16816536)

  • 1. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
    Ducreux M; Bouche O; Pignon JP; Mousseau M; Raoul JL; Cassan P; Leduc B; Berger C; Dunant A; Fournet J; Bedenne L;
    Oncology; 2006; 70(3):222-30. PubMed ID: 16816536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
    Borget I; Aupérin A; Pignon JP; Abbas M; Bouché O; Mousseau M; Raoul JL; Bedenne L; Cassan P; Clavero-Fabri MC; Stremsdoerfer N; Nasca S; Queuniet AM; Ducreux M;
    Oncology; 2006; 71(1-2):40-8. PubMed ID: 17344670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial].
    Locher C; Auperin A; Boige V; Alzieu L; Pignon JP; Abbas M; Ducreux M
    Gastroenterol Clin Biol; 2001; 25(8-9):749-54. PubMed ID: 11598535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
    Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
    Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1).
    Baumgaertner I; Quinaux E; Khalil A; Louvet C; Buyse M; de Gramont A; André T;
    Clin Colorectal Cancer; 2010 Apr; 9(2):E5-10. PubMed ID: 20378497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of infusional biomodulated 5-fluorouracil in metastatic colorectal cancer after raltitrexed failure.
    Decoster L; Neyns B; Akouaouach H; Fontaine C; Schallier D; De Grève JL
    Anticancer Res; 2004; 24(3b):2037-40. PubMed ID: 15274397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
    Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
    Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
    J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.
    Köhne CH; Bedenne L; Carrato A; Bouché O; Popov I; Gaspà L; Valladares M; Rougier P; Gog C; Reichardt P; Wils J; Pignatti F; Biertz F
    Eur J Cancer; 2013 May; 49(8):1868-75. PubMed ID: 23571150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer.
    Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Chen PM
    Hepatogastroenterology; 2000; 47(36):1599-603. PubMed ID: 11149011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
    Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
    J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
    Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
    Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
    Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
    Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress in development of chemotherapy of colorectal carcinoma].
    Köhne CH
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():33-7. PubMed ID: 8692117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).
    Popov I; Carrato A; Sobrero A; Vincent M; Kerr D; Labianca R; Raffaele Bianco A; El-Serafi M; Bedenne L; Paillot B; Mini E; Sanches E; Welch J; Collette L; Praet M; Wils J
    Eur J Cancer; 2008 Oct; 44(15):2204-11. PubMed ID: 18707870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
    Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
    Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.
    Nogué M; Salud A; Batiste-Alentorn E; Saigí E; Losa F; Cirera L; Méndez M; Campos JM; Galan A; Escudero P; Arcusa A; Manzano H; de Mendizábal EV; de Olaguer JP; Boleda M; Guasch I; Vicente P
    Eur J Cancer; 2005 Oct; 41(15):2241-9. PubMed ID: 16214045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.